Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enalapril worldwide experience.

R O Davies, J D Irvin, D K Kramsch

    The American Journal of Medicine
    |August 20, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Global transcriptional differences in myokine and inflammatory genes in muscle of mature steer progeny are related to maternal lactation diet and muscle composition.

    Physiological genomics·2018
    Same author

    Increased daily movement associates with reduced mortality among COPD patients having systemic inflammation.

    International journal of clinical practice·2016
    Same author

    Monitoring the long-term safety of lipid lowering therapy.

    The International journal of risk & safety in medicine·2013
    Same author

    Serum lipids in Canadian physicians.

    Canadian Medical Association journal·2010
    Same author

    Dosage, compliance and bioavailability in perspective.

    Canadian Medical Association journal·2010
    Same author

    Pulmonary nociceptors are potentially connected with neuroepithelial bodies.

    Advances in experimental medicine and biology·2006
    Same journal

    Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

    The American journal of medicine·2026
    Same journal

    GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

    The American journal of medicine·2026
    Same journal

    Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

    The American journal of medicine·2026
    Same journal

    Cave Canem - Beware of the Dog.

    The American journal of medicine·2026
    Same journal

    Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

    The American journal of medicine·2026
    Same journal

    Mesenteric panniculitis.

    The American journal of medicine·2026
    See all related articles

    Enalapril effectively treats essential hypertension in 54-66% of patients, showing comparable efficacy to diuretics and beta blockers. It is better tolerated than captopril and mitigates some diuretic side effects.

    Area of Science:

    • Pharmacology and Therapeutics
    • Cardiovascular Medicine

    Background:

    • Essential hypertension is a widespread condition requiring effective and well-tolerated treatments.
    • Angiotensin-converting enzyme (ACE) inhibitors represent a key class of antihypertensive medications.

    Purpose of the Study:

    • To evaluate the worldwide clinical experience and efficacy of enalapril in managing hypertension.
    • To compare the effectiveness and tolerability of enalapril with existing antihypertensive agents like diuretics and beta blockers.
    • To assess the safety profile of enalapril, particularly in relation to captopril and its side effects.

    Main Methods:

    • Review of worldwide clinical data and patient experiences with enalapril.
    • Comparative analysis of enalapril's efficacy against diuretics and beta blockers in essential hypertension.

    Related Experiment Videos

  • Assessment of enalapril's safety profile, including comparison with captopril and evaluation of metabolic effects when combined with hydrochlorothiazide.

    • Main Results:

    • Enalapril demonstrates good to excellent responses in 54-66% of patients with essential hypertension.
    • Enalapril exhibits comparable efficacy to diuretics and beta blockers, with enhanced response in patients dependent on the renin-angiotensin system.
    • Enalapril is better tolerated than captopril, with fewer instances of side effects like rash and taste disturbance; it also attenuates hydrochlorothiazide-induced hypokalemia.

    Conclusions:

    • Enalapril is a highly effective and well-tolerated treatment option for essential hypertension.
    • Combination therapy with enalapril and hydrochlorothiazide provides excellent long-term blood pressure control.
    • Enalapril offers a favorable safety profile compared to captopril, making it a valuable therapeutic choice.